Testing two Privigen doses in children with CIDP
Compares two Privigen dose levels in children aged 2 to 17 with CIDP.
Plain-language title generated from the registry record
Registry title: Two Dose Levels of Privigen in Pediatric CIDP
Key facts
- Where
- Akron, Flower Mound, Iowa City, Los Angeles, Memphis, Norfolk, Philadelphia, Phoenix, and Seattle, United StatesSee the 9 sites
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 2 and 17 years old?
Source: NCT03684018, who can take part
Where in United States
- Akron Children's HospitalAkron, United StatesNo longer taking part
- Neurology Rare Disease CenterFlower Mound, United StatesTaking people
- University of Iowa Hospitals and ClinicsIowa City, United StatesNo longer taking part
- Children's Hospital of Los AngelesLos Angeles, United StatesNo longer taking part
- Le Bonheur Children's HospitalMemphis, United StatesNo longer taking part
- Children's Specialty GroupNorfolk, United StatesNo longer taking part
- Children's Hospital of PhiladelphiaPhiladelphia, United StatesTaking people
- Phoenix Children s HospitalPhoenix, United StatesNo longer taking part
- Seattle Children's HospitalSeattle, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- CSL Behring
- Trial code
- NCT03684018
- Record updated
- 1 June 2026
- Original description
A randomized, open-label, prospective, multicenter study designed to investigate 2 dose levels in pediatric subjects 2 to ≤ 17 years of age with confirmed or possible CIDP, either previously exposed to IVIG treatment or unexposed to IVIG treatmentRead full original descriptionShow less
Randomized Study of Two Dose Levels of Privigen in Pediatric CIDP
A randomized, open-label, prospective, multicenter study designed to investigate 2 dose levels in pediatric subjects 2 to ≤ 17 years of age with confirmed or possible CIDP, either previously exposed to IVIG treatment or unexposed to IVIG treatment
Inclusion: - Male or female subjects 2 to ≤ 17 years of age with confirmed or possible CIDP.
Exclusion: -History or family history of inherited neuropathy; -History of thrombotic episode; -Known or suspected hypersensitivity to Privigen; -Known allergic or other severe reactions to blood products; - Absence of CIDP symptoms; -Diagnosed developmental delay or regression; -Female subject of childbearing potential either not using or not willing to use a medically reliable method of contraception or not sexually abstinent during the study; -Pregnant or breastfeeding mother".